Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07197268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Bainbridge-Ropers Syndrome (BRPS) due to a pathogenic, de novo nonsense variant in ASXL3
Trial Details
NCT Number NCT07197268
Lead Sponsor n-Lorem Foundation
Collaborators: University of North Carolina, Chapel Hill
Conditions
(from sponsor)		 Bainbridge-Ropers Syndrome
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov